Malathion

Summary

Malathion (CHEMBL1200468) is an approved small molecule (ATC P03AX03); indicated across 2 conditions including parasitic infectious disease and lice infestation.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03AX03
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 330.4 Da · C10H19O6PS2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200468
Name	Malathion
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4004
ChEBI	CHEBI:141474
ATC	P03AX03
Molecular formula	C10H19O6PS2
Molecular weight	330.4
InChIKey	JXSJBGJIGXNWCI-UHFFFAOYSA-N

SMILES: CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC

IUPAC name: diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate

ChEBI definition: A diester that is diethyl succinate in which position 2 is substituted by a (dimethoxyphosphorothioyl)thio group.

Also known as: 8059HC, Cythion, Derbac-m, ENT 17,034, ENT-17034, Malathion, NSC-6524, OVIDE, Ovide, Organoderm, Prioderm, Quellada-m

Patent coverage: 11,713 distinct patent families (36,800 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Muscarinic acetylcholine receptor M1, Adenosine receptor A1, Polyunsaturated fatty acid lipoxygenase ALOX15, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP3A4	6	Potency	1000	nM	CHEMBL_ACT_5006117
CYP3A4	6	Potency	1000	nM	CHEMBL_ACT_5070929
HSD17B10	5.4	Potency	3981	nM	CHEMBL_ACT_4821733
ALDH1A1	5.25	Potency	5623	nM	CHEMBL_ACT_4196539

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067
lice infestation	3	MONDO:0003472	MONDO:0003472

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00819520	PHASE3	COMPLETED	Ivermectin in the Treatment of Head Lice

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).